Health ❯Medical Research ❯Clinical Trials

Drug Development

PAR1 Targeting FDA-Approved Treatments Neurosurgery Teclistamab Oncology

PAR1 Receptor Drives Lung Lymphatic Remodeling to Accelerate Fluid Clearance

Researchers are exploring ways to target PAR1 on lung lymphatics without disrupting its function in blood vessels

Merck Completes €3 Billion Springworks Deal in Largest Pharma Acquisition Since 2007

Grandmother in Remission After 25-Year Myeloma Battle Thanks to Experimental Drug

Living Human Brain Tissue Provides Breakthrough Insights Into Alzheimer’s Disease